NGX-4010 for the Treatment of Postherpetic Neuralgia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00061776|
Recruitment Status : Completed
First Posted : June 4, 2003
Last Update Posted : March 6, 2008
|Condition or disease||Intervention/treatment||Phase|
|Herpes Zoster Neuralgia Pain Peripheral Nervous System Diseases Shingles||Drug: Capsaicin Dermal Patch||Phase 2 Phase 3|
Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin).
Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Official Title:||A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00061776
Show 28 Study Locations